インスリンの市場規模、シェア、動向分析レポート：製品タイプ別、用途別、流通チャネル別、地域別、セグメント予測、2025年～2030年

インスリン市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界のインスリンの市場規模は2030年までに232億1,000万米ドルに達すると推定され、2025年から2030年にかけて3.7%のCAGRで成長すると予測されています。

同市場は、Novo Nordisk A/S、Sanofi、Eli Lilly and Companyなどの企業が支配する寡占市場です。糖尿病の罹患率の増加とインスリンデリバリーにおける製剤の進歩が成長を促進する主な要因です。しかし、バイオシミラーやGLP-1 RAのような2型糖尿病治療薬の存在は、市場の成長をある程度減速させる可能性があります。

糖尿病は、世界で最も急速に増加している慢性疾患の一つです。その有病率は過去数十年にわたって着実に増加しています。有病率は低・中所得国で急速に増加しており、これらの国では成人の4人に3人が糖尿病を患っています。2021年の国際糖尿病連合（IDF）のデータによると、2030年には約6億4,300万人、2045年には7億8,300万人が糖尿病を患うとされています。さらに、高齢者人口と肥満人口の増加も成長を促進する要因のひとつです。肥満人口は2型糖尿病を開発するリスクがあります。WHOによると、2020年には19億人の成人が過体重であることが判明し、その年齢層の人口の39％を占める。

インスリン送達システムにおける製剤の進歩が開発されており、その発売は予測期間にわたって市場を推進すると思われます。2019年12月には、Tandem Diabetes Care社の相互運用可能なデバイスであるControl-IQが米国でFDAの販売承認を取得しました。これは、他の相互運用可能なデバイスと使用できる自動インスリン投与アルゴリズムです。

Eli Lilly and Company、Novo Nordisk A/S、Sanofiの製造企業上位3社が独占しています。これらの企業が市場シェアの90％以上を占めています。市場の寡占化と特許保護のため、インスリンのコストは高いです。したがって、製品の高コストが業界の成長を阻害する可能性があります。

COVID-19パンデミックは業界に悪影響を与えました。糖尿病などの慢性疾患を持つ人々は、緊急医療や日常医療に大きな支障をきたしました。NCBIの記事によると、アメリカの糖尿病患者の約3,000万人のうち、約750万人がインスリンに依存しています。インスリンの配給や買いだめはすでに蔓延している問題で、パンデミックの最中には供給への懸念からさらに増加しました。しかし、いくつかの国では、COVID-19の影響が2020年第3四半期以降に減少し、市場の回復を後押ししました。

インスリン市場レポートハイライト

• 長時間作用型インスリン製剤が市場を独占し、2024年の売上高シェアは52.4%で最大でした。
• 1型糖尿病セグメントが市場を独占し、2024年には78.8%の最大売上シェアを占めました。
• アナログインスリン部門が市場を独占し、ヒトインスリンに対する優位性により2024年に87.3%の最大収益シェアを占めました。
• 小売薬局セグメントが市場を独占し、2024年に90.0％の最大収益シェアを占めました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 インスリン市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• インスリン市場分析ツール
  • 業界分析 - ポーターのファイブフォース分析
  • PESTEL分析

第4章 インスリン市場： 製品別の推定・動向分析

• セグメントダッシュボード
• インスリン市場：製品別の変動分析
• インスリン市場：製品別の展望
• 市場規模と予測および動向分析（2018年～2030年）
• 速効型インスリン
• 持続性インスリン
• 複合インスリン
• バイオシミラー
• その他

第5章 インスリン市場： タイプ別の推定・動向分析

• セグメントダッシュボード
• インスリン市場：タイプ別の変動分析
• インスリン市場：タイプ別の展望
• 市場規模と予測および動向分析（2018年～2030年）
• ヒトインスリン
• インスリンアナログ

第6章 インスリン市場： 用途別の推定・動向分析

• セグメントダッシュボード
• インスリン市場：用途別の変動分析
• インスリン市場：用途別の展望
• 市場規模と予測および動向分析（2018年～2030年）
• 1型糖尿病
• 2型糖尿病

第7章 インスリン市場： 流通チャネル別の推定・動向分析

• セグメントダッシュボード
• インスリン市場：流通チャネル別の変動分析
• インスリン市場：流通チャネル別の展望
• 市場規模と予測および動向分析（2018年～2030年）
• 病院
• 小売薬局
• その他

第8章 インスリン市場： 地域別の推定・動向分析

• 地域ダッシュボード
• 市場規模と予測および動向分析（2018年～2030年）
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 市場参入企業の分類
• 主要市場参入企業による最近の動向と影響分析
• 企業市場シェア分析、2024年
• 主要企業プロファイル
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi
  • Biocon Ltd
  • Wockhardt
  • Boehringer Ingelheim International GmbH
  • Julphar
  • United Laboratories International Holdings Limited
  • Tonghua Dongbao Pharmaceutical Co. Ltd.

List of Tables

• Table 1. List of Secondary Sources
• Table 2. List of Abbreviations
• Table 3. List of secondary sources
• Table 4. List of Abbreviations
• Table 5. North America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 6. North America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 7. North America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 8. North America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 9. U.S. insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 10. U.S. insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 11. U.S. insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 12. U.S. insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 13. Canada insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 14. Canada insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 15. Canada insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 16. Canada insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 17. Europe insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 18. Europe insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 19. Europe insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 20. Europe insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 21. UK insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 22. UK insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 23. UK insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 24. UK insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 25. Germany insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 26. Germany insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 27. Germany insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 28. Germany insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 29. France insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 30. France insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 31. France insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 32. France insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 33. Italy insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 34. Italy insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 35. Italy insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 36. Italy insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 37. Spain insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 38. Spain insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 39. Spain insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 40. Spain insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 41. Asia Pacific insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 42. Asia Pacific insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 43. Asia Pacific insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 44. Asia Pacific insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 45. Japan insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 46. Japan insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 47. Japan insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 48. Japan insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 49. China insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 50. China insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 51. China insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 52. China insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 53. India insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 54. India insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 55. India insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 56. India insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 57. Australia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 58. Australia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 59. Australia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 60. Australia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 61. South Korea insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 62. South Korea insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 63. South Korea insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 64. South Korea insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 65. Latin America insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 66. Latin America insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 67. Latin America insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 68. Latin America insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 69. Brazil insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 70. Brazil insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 71. Brazil insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 72. Brazil insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 73. Mexico insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 74. Mexico insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 75. Mexico insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 76. Mexico insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 77. Argentina insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 78. Argentina insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 79. Argentina insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 80. Argentina insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 81. MEA insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 82. MEA insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 83. MEA insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 84. MEA insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 85. South Africa insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 86. South Africa insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 87. South Africa insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 88. South Africa insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 89. Saudi Arabia insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 90. Saudi Arabia insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 91. Saudi Arabia insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 92. Saudi Arabia insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD Million)
• Table 93. UAE insulin market estimates and forecasts, by product, 2018 - 2030 (USD Million)
• Table 94. UAE insulin market estimates and forecasts, by application, 2018 - 2030 (USD Million)
• Table 95. UAE insulin market estimates and forecasts, by type, 2018 - 2030 (USD Million)
• Table 96. UAE insulin market estimates and forecasts, by distribution channel, 2018 - 2030 (USD) Million
• Table 97. List of key distributors

List of Figures

• Fig. 1 Market research approaches
• Fig. 2 Value chain-based sizing & forecasting
• Fig. 3 Market formulation & validation
• Fig. 4 Insulin market segmentation
• Fig. 5 Market driver analysis (current & future impact)
• Fig. 6 Market restraint analysis (current & future impact)
• Fig. 7 SWOT analysis, by factor (political & legal, economic and technological)
• Fig. 8 Porter's five forces analysis
• Fig. 9 Global insulin market: Product type outlook and key takeaways
• Fig. 10 Global insulin market: Product type movement analysis
• Fig. 11 Rapid-acting insulin market estimates and forecast, 2018-2030 (USD Million)
• Fig. 12 Long-acting insulin market estimates and forecast, 2018-2030 (USD Million)
• Fig. 13 Combination Insulin market estimates and forecast, 2018-2030 (USD Million)
• Fig. 14 Biosimilar market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 15 Others market estimates and forecast, estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 16 Global insulin market: type outlook and key takeaways
• Fig. 17 Global insulin market: Type movement analysis
• Fig. 18 Human insulin market estimates and forecast, 2018-2030 (USD Million)
• Fig. 19 Insulin Analog market estimates and forecast, 2018-2030 (USD Million)
• Fig. 20 Global Insulin market: Application type outlook and key takeaways
• Fig. 21 Global insulin market: Application type movement analysis
• Fig. 22 Type 1 diabetes mellitus market estimates and forecast, 2018-2030
• Fig. 23 Type 2 diabetes mellitus market estimates and forecast, 2018-2030
• Fig. 24 Global insulin market: Distribution channel outlook and key takeaways
• Fig. 25 Global insulin market: Distribution channel movement analysis
• Fig. 26 Hospital pharmacy market estimates and forecast, 2018-2030 (USD Million)
• Fig. 27 Retail pharmacy market estimates and forecast, 2018-2030 (USD Million)
• Fig. 28 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 North America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 30 US Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 31 Canada Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 32 Mexico Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 33 Europe Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 34 UK Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 35 Germany Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 36 France Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 37 Italy Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 38 Spain Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 39 Denmark Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 40 Sweden Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 41 Norway Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 42 Asia Pacific Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 43 Japan Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 44 China Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 45 India Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 46 Australia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 47 Thailand Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 48 South Korea Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 49 Latin America Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 50 Brazil Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 51 Argentina Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 52 MEA Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 53 South Africa Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 54 Saudi Arabia Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 55 UAE Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 56 Kuwait Insulin market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 57 List of key emerging company's/disruptors/innovators

Insulin Market Growth & Trends:

The global insulin market size is estimated to reach USD 23.21 billion by 2030, registering to grow at a CAGR of 3.7% from 2025 to 2030 according to a new report by Grand View Research, Inc. It is an oligopolistic space dominated by companies such as Novo Nordisk A/S, Sanofi, and Eli Lilly and Company. The increasing incidence of diabetes and formulation advancements in insulin delivery are the primary factors driving growth. However, the presence of biosimilars and drugs such as GLP-1 RAs for the treatment of type 2 diabetes can slow down market growth to a certain extent.

Diabetes is one of the fastest-growing chronic diseases in the world. Its prevalence has increased steadily over the past few decades. The prevalence of the disease is growing rapidly in low- and middle-income countries; three in four adults live with diabetes in these countries. According to the International Diabetes Federation (IDF) data from 2021, approximately 643 million individuals will have diabetes by 2030 and 783 million by 2045. In addition, the increase in geriatric and obese populations is another factor driving growth. The overweight population is at risk of developing type 2 diabetes mellitus. According to WHO, in 2020, 1.9 billion adults were found to be overweight, accounting for 39% of the population within that age group.

Formulation advancements in insulin delivery systems are being developed, the release of which is likely to propel the market over the forecast period. In December 2019, Tandem Diabetes Care's Control-IQ, an interoperable device, received FDA authorization for marketing in the U.S. It is an automated insulin dosing algorithm that can be used with other interoperable devices.

The top three manufacturing companies, Eli Lilly and Company, Novo Nordisk A/S, and Sanofi, hold a monopoly. These companies hold more than 90% of the market share. Owing to the oligopolistic nature of the market and patent protection, the cost of insulin is high. Hence, the high cost of products could impede industry growth.

The COVID-19 pandemic caused a detrimental impact on the industry. Individuals with chronic illnesses, such as diabetes, have experienced substantial disruptions in emergency and routine medical care. According to an NCBI article, out of ~30 million diabetic patients in America, about 7.5 million are dependent on insulin. Insulin rationing or hoarding has already been a rampant issue, which increased further amid the pandemic due to supply concerns. However, in several countries, the effect of COVID-19 declined to post the third quarter of 2020, which helped the market regain traction.

Insulin Market Report Highlights:

• The long-acting insulin segment dominated the market and accounted for the largest revenue share of 52.4% in 2024.
• The type 1 diabetes mellitus segment dominated the market and accounted for the largest revenue share of 78.8% in 2024, driven by the rising incidence of this autoimmune condition among children and adults.
• The analog insulin segment dominated the market and accounted for the largest revenue share of 87.3% in 2024 due to its advantages over human insulin.
• The retail pharmacy segment dominated the market and accounted for the largest revenue share of 90.0% in 2024.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Product
  • 1.2.2. Type
  • 1.2.3. Application
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. Insulin Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increase in prevalence of diabetes
    • 3.2.1.2. Increase in geriatric and obese population
    • 3.2.1.3. Formulation advancements in insulin delivery systems
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of insulin
    • 3.2.2.2. Poor reimbursement policies
    • 3.2.2.3. Launch of insulin biosimilars and increasing penetration of glp-1 agonists
• 3.3. Insulin Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. Insulin Market: Product Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Insulin Market: Product Movement Analysis
• 4.3. Insulin Market by Product Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 4.5. Rapid-Acting Insulin
  • 4.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Long-Acting Insulin
  • 4.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Combination Insulin
  • 4.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.8. Biosimilar
  • 4.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Insulin Market: Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Insulin Market: Type Movement Analysis
• 5.3. Insulin Market by Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 5.5. Human Insulin
  • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Insulin Analog
  • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Insulin Market: Application Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Insulin Market: Application Movement Analysis
• 6.3. Insulin Market by Application Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 6.5. Type 1 Diabetes Mellitus
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Type 2 Diabetes Mellitus
  • 6.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Insulin Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Insulin Market: Distribution Channel Movement Analysis
• 7.3. Insulin Market by Distribution Channel Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
• 7.5. Hospitals
  • 7.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Retail Pharmacies
  • 7.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Others
  • 7.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Insulin Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size & Forecasts Trend Analysis, 2018 to 2030:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2024
• 9.4. Key Company Profiles
  • 9.4.1. Novo Nordisk A/S
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Eli Lilly and Company
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. Sanofi
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Biocon Ltd
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. Wockhardt
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. Boehringer Ingelheim International GmbH
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Julphar
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. United Laboratories International Holdings Limited
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Tonghua Dongbao Pharmaceutical Co. Ltd.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives